R&D-focused biotech reported a net loss of PLN 9.1M for 9M 2025, with minimal sales and increased R&D spending. Key projects Genomtec ID and OncoSNAAT advanced, supported by new patents and a PLN 10.8M capital raise, but future results depend on successful commercialization and external funding.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.